Compugen Ltd (CGEN)

[shub]

At the risk of being redundant...Check this out!

Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, disclosed today new animal model results demonstrating restoration of immune tolerance by CGEN-15001, the Company's lead candidate for treatment of autoimmune diseases. Importantly, the immune tolerance established by CGEN-15001 was shown to be antigen-specific, indicating that treatment with CGEN-15001 has the potential to not only generate a durable response, but also to avoid the global immune suppression generated by other therapeutic agents for autoimmune diseases. CGEN-15001 is an Fc fusion protein based on a Compugen-discovered novel immune checkpoint protein.

That means we can treat and protect specific autoimmune disease targets...some of the most common and intractable curses of mankind!

If this proves out, we should come out of this with bulging pockets and feeling a whole lot better besides!